The subiculum: A potential site of action for novel antipsychotic drugs?

Molecular Psychiatry

Volumn 1, Issue 5, 1996, Pages 380-387

  Greene, J R T ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Behaviour; Hippocampus; Nitric oxide; Schizophrenia; Somatostatin

Indexed keywords

NEUROLEPTIC AGENT;

ANIMAL; DRUG EFFECT; HIPPOCAMPUS; HUMAN; PATHOPHYSIOLOGY; RAT; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HIPPOCAMPUS; HUMANS; RATS; SCHIZOPHRENIA;

EID: 0030275473     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Weinberger DR. Schizophrenia: from neuropathology to neurodevelopment. Lancet 1995; 346: 552-557.
2. Johnstone EC. Schizophrenia: problems in clinical practice. Lancet 1993; 341: 536-538.
3. Amaral DG, Witter MP. Hippocampal formation. In: Paxinos G (ed). The Rat Nervous System, 2nd edition. Academic Press: London, 1995, pp 443-493.
4. Gould RJ, Murphy KMM, Reynolds IJ, Snyder S. Anti-schizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci (USA) 1983; 80: 5122-5125.
5. Dinan TG, Crunelli V, Kelly JS. Neuroleptics decrease calcium-activated potassium conductance in hippocampal pyramidal cells. Brain Res 1987; 407: 159-162.
6. Bymaster FP, Calligaro DO, Falcone JF, Marsh AD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical anti-psychotic olanzapine. Neuropsychopharmacology 1996; 14(2): 87-96.
7. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-718.
8. Totterdell S, Smith AD. Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat 1989; 2: 285-298
9. O'Donnell P, Grace AA. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci 1995; 15: 3622-3639.
10. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD. The neuropsychology of schizophrenia. Behav Brain Sci 1991; 14: 1-84.
11. Gray JA, Joseph MH, Hemsley DR, Toung AMJ, Warburton EC, Boulenguez P, Grigoryan GA, Peters SL, Rawlins JNP, Taib C-T, Yee BK, Cassaday H, Weiner I, Gal G, Gusak O, Joel D, Shadach E, Shalev U, Tarrasch R, Feldon JE. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res 1995; 71: 19-31.
12. Anscombe R. The disorder of consciousness in schizophrenia. Schizophrenia Bull 1987; 13: 241-260.
13. Braff DL, Grillon G, Geyer MA. Gating and habituation of startle reflex in schizophrenic: patients. Arch Gen Psychiatry 1992; 49: 206-215.
14. Feldon J, Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiat Res 1992; 26: 367-382.
15. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Arch Gen Psychiatry 1990; 47: 181-188.
16. Gray NS, Pilowsky LS, Gray JA, Kerwin RW. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Res 1995; 17: 95-107.
17. Wilkinson LS, Miltleman G, Torres E, Humby T, Hall FS, Robbins TW. Enhancement of amphetamine-induced locomotor activity and dopamine release in nucleus accumbens following excitotoxic lesions of the hippocampus. Behav Brain Res 1993; 55: 143-150.
18. Burns LH, Robbins TW, Everitt BJ. Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of D-amphetamine. Behav Brain Res 1993; 55: 167-183.
19. Caine SB, Geyer MA, Swerdlow NR. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Nouropsychopharmacology 1995; 12: 139-145.
20. Killcross AS, Dickinson A, Robbins TW. Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 1994; 115: 196-205.
21. Joseph MH. Latent inhibition: interpretation of amphetamine effects in novel paradigms. Psychopharmacology 1995; 118: 101-103.
22. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskin GE, Geyer MA. Increased sensitivity to the sensorimotor gating disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology 1995; 122: 27-34.
23. Caine SB, Geyer MA, Swerdlow NR. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. Pharmacol Biochem Behav 1992; 43: 1201-1208.
24. Clark AJM, Feldon J, Rawlins JNP. Aspiration lesion of rat ventral hippocampus disinhibit responding to conditioned suppression or extinction, but spare latent inhibition and the partial reinforcement extinction effect. Neuroscience 1992; 48: 821-829.
25. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 1993; 34: 361-372.
26. Feldon J, Avnimelech-Gigus N, Weiner I. The effects of pre- and postweaning rearing conditions on latent inhibition and partial reinforcement extinction effect in male rats. Behav Neurol Biol 1990; 53: 189-204.
27. McCormick DA, Prince DA. Post-natal development of electrophysiologioal properties of rat cerebral cortical pyramidal neurons. J Physiol (Lond) 1987; 393: 743-752.
28. Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ, Trojanowski JQ. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 1995; 152: 738-748.
29. Arnold SE, Lee VM, Gur RE, Trojanowski JQ. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci (USA) 1991; 88: 10850-10854.
30. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995; 66: 309-319.
31. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry 1990; 157: 72-76.
32. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 1991; 1: 103-116.
33. Chan-Palay V. Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia. J Comp Neurol 1987; 260: 201-233.
34. West MJ. Regionally specific: loss of neurons in the aging human hippocampus. Neurobiol Aging 1993; 14: 287-293.
35. Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens HGC, Bacarese-Hamilton AJ, McGregor G, O'Shaughnessey D, Polak JM, Bloom SR. Peptides, the limbic lobe and schizophrenia. Brain Res 1983; 288: 199-211.
36. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. Neuropeptide deficits in schizophrenia vs Alzheimer's disease cerebral cortex. Biol Psych 1996; 39: 82-91.
37. Somogyi P, Hodgson AJ, Smith AD, Nunzi MG, Gorio A, Wu J-Y. Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material. J Neurosci 1984; 4: 2590-2603.
38. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in profrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991; 48: 996-1001.
39. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE, Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe in schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993; 50: 178-187.
40. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman GA, Jones EG. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993; 50: 169-177.
41. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996; 53: 425-436.
42. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophrenia Bull 1993; 19: 431-445.
43. Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence for dysfunction of the prefrontal-limbic network in schizophrenia: an MRI and rCBF study of discordant monozygotic twins. Am J Psychiatry 1992; 149: 890-897.
44. Ranck JB. Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. Exp Neurol 1973; 41: 462-531.
45. Mason AJR. Electrophysiology and burst-firing of rat subicular pyramidal neurons in vitro - a comparison with area CA1. Brain Res 1993; 600: 174-178.
46. Taube JS. Electrophysiological properties of neurons in the rat subiculum in vitro. Exp Brain Res 1993; 96(2): 304-318.
47. Stewart M, Wong RKS. Intrinsic properties and evoked responses of guinea pig subicular neurons in vitro. J Neurophysiol 1993; 70: 232-245.
48. Finch DM, Tan AM, Isokawa-Akesson M. Feedforward inhibition of the rat entorhinal cortex and subicular complex. J Neurosci 1988; 8: 2213-2226.
49. Hablitz JJ. Mechanisms regulating synchronization of hippocampal epileptiform activity. In: Heinemann U, Kell M, Neher E, Springer W (eds). Calcium Electrogenesis and Neuronal Functioning. Springer-Verlag: Berlin, 1986, pp 337-344.
50. Greene JRT, Mason AJR. Neuronal diversity in the subiculum: correlations with the effects of somatostatin on intrinsic properties and GABA mediated IPSPs in vitro. J Neurophysiol 1996; (in press).
51. Namura S, Takada M, Kikuchi H, Mizuno N. Topographical organization of subicular neurons projecting to subcortical regions. Brain Res Bull 1994; 35: 221-231.
52. Greene JRT, Mason A. Effects of somatostatin and related peptides on the membrane potential and input resistance of rat ventral subicular neurons, in vitro. J Pharmacol Exp Ther 1996; 267: 426-432.
53. Reubi JC, Cortes R, Maurer R, Probst A, Palacios JM. Distribution of somatostatin receptors in the human brain: an autoradiographic study. Neuroscience 1986; 18: 329-346.
54. Breder CD, Yamada Y, Yasuda K, Seino S, Saper CB, Bell GI. Differential expression of somatostatin receptor subtypes in brain. J Neurosci 1992; 12: 3920-3934.
55. Leroux P, Weissmann D. Pujol J-F, Vaudry H. Quantitative autoradiography of somatostatin receptors in the rat limbic system. J Comp Neurol 1993; 331: 389-401.
56. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carroll A-M, Patel YC, Schonbrunn A, Taylor JE, Reisine T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
57. Senaris RM, Humphrey PPA, Emson PC. Distribution of somatostatin receptors 1, 2 and 3 mRNA in rat brain and pituitary. Eur J Neurosci 1994; 6: 1883-1896.
58. Harrington KA, Schindler M, Humphrey PPA, Emson PC. Expression of messenger RNA for somatostatin receptor subtype 4 in adult rat brain. Neurosci Lett 1995; 188: 17-20.
59. Aylward RLM, Totterdell S. Neurons in the ventral subiculum, amygdala and entorhinal cortex which project to the nucleus accumbens - their input from somatostatin-immunoreactive boutons. J Chem Neuroanat 1993; 6: 31-42.
60. Totterdell S, Smith AD. Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens. Neuroscience 1986; 19: 181-192.
61. Dodd J, Kelly JS. The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res 1981; 205: 337-350.
62. Valtschanoff JG, Weinberg RJ. Kharazia VN, Nakane M, Schmidt HHW. Neurons in rat hippocampus that synthesize nitric oxide. J Comp Neurol 1993; 331: 111-121.
63. Egberongbe YI, Gentleman SM, Falkai P, Bogerts B, Polak JM, Roberts GW. The distribution of nitric oxide synthase immunoreactivity in the human brain. Neuroscience 1994; 59: 561-578.
64. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988; 336: 385-388.
65. Larkman AU, Jack JJB. Synaptic plasticity: hippocampal LTP. Curr Opin Neurobiol 1995; 5: 324-334.
66. Nicoll RA, Malenka RC. Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature 1995; 377: 115-118.
67. Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM. Snyder SH. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995; 378: 383-386.
68. Vincent SR. Nitric oxide: a radical neurotransmitter in the central nervous system. Prog Neurobiol 1994; 42: 129-160.
69. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press: London, 1982.